Design of Inhibitors for S100B.
S100B interacts with the p53 protein in a calcium-dependent manner and down-regulates its function as a tumor suppressor. Therefore, inhibiting the S100B-p53 interaction represents a new approach for restoring functional wild-type p53 in cancers with elevated S100B such as found in malignant melanoma. A discussion of the biological rational for targeting S100B and a description of methodologies relevant to the discovery of compounds that inhibit S100B-p53 binding, including computational techniques, structural biology techniques, and cellular assays, is presented.
Markowitz
Joseph
J
University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Maryland 21201, USA.
Mackerell
Alexander D
AD
Carrier
France
F
Charpentier
Thomas H
TH
Weber
David J
DJ
D014408:Biomarkers, Tumor; D002118:Calcium / Q000378:metabolism; D017076:Computer-Aided Design; D015195:Drug Design; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D015394:Molecular Structure; D009414:Nerve Growth Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012995:Solubility; D013050:Spectrometry, Fluorescence; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D014408:Biomarkers, Tumor; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human; D016159:Tumor Suppressor Protein p53; D002118:Calcium